ObjectivesChronic infection with hepatitis C virus (HCV) was previously the leading indication for liver transplant (LT) in the United States. However, since 2014 the use of direct-acting antivirals (DAAs) has decreased the chronic HCV burden, while the prevalence of nonalcoholic steatohepatitis (NASH) has risen substantially through the last decade. Both gender and ethnic disparities in indications for LT have been shown in the past but no data on this have been reported since the implementation of DAAs.MethodsWe assessed changes in etiologies for LT listing and in gender and ethnic differences in those listed for LT. Adult patients registered for LT in the United Network for Organ Sharing/Organ Procurement and Transplantation Network data...
Although hepatitis B and C have been the main drivers of hepatocellular carcinoma (HCC), nonalcoholi...
Background and Objectives: Non‐alcoholic steatohepatitis (NASH) has become the leading indication fo...
Background and Aims: With the availability of direct-acting antiviral (DAA) therapy for hepatitis C ...
Aim: Worldwide, hepatocellular cancer (HCC) is the fourth leading cause of cancer death and occurs 3...
Hepatitis C virus infection has been the most common etiology in HCC-related liver transplantation (...
Hepatitis C virus infection has been the most common etiology in HCC-related liver transplantation (...
Background: Female gender has been reported to be a risk factor for graft loss after liver transplan...
© 2019 Editrice Gastroenterologica Italiana S.r.l. Background and aims: With the availability of dir...
Background. Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in...
It has been recently suggested that the risk of graft loss after liver transplantation (LT) may incr...
Direct-acting antiviral (DAA) therapy, recently approved for patients with decompensated cirrhosis (...
Chronic hepatitis C virus (HCV) infection is a leading cause for orthotopic liver transplantation (O...
BACKGROUND: Hospital admissions are common among patients with cirrhosis, but patient factors associ...
The worldwide increase in obesity and diabetes has led to predictions that nonalcoholic steatohepati...
Purpose: Nonalcoholic steatohepatitis (NASH) is an increasing cause of liver transplantation (LT) wo...
Although hepatitis B and C have been the main drivers of hepatocellular carcinoma (HCC), nonalcoholi...
Background and Objectives: Non‐alcoholic steatohepatitis (NASH) has become the leading indication fo...
Background and Aims: With the availability of direct-acting antiviral (DAA) therapy for hepatitis C ...
Aim: Worldwide, hepatocellular cancer (HCC) is the fourth leading cause of cancer death and occurs 3...
Hepatitis C virus infection has been the most common etiology in HCC-related liver transplantation (...
Hepatitis C virus infection has been the most common etiology in HCC-related liver transplantation (...
Background: Female gender has been reported to be a risk factor for graft loss after liver transplan...
© 2019 Editrice Gastroenterologica Italiana S.r.l. Background and aims: With the availability of dir...
Background. Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in...
It has been recently suggested that the risk of graft loss after liver transplantation (LT) may incr...
Direct-acting antiviral (DAA) therapy, recently approved for patients with decompensated cirrhosis (...
Chronic hepatitis C virus (HCV) infection is a leading cause for orthotopic liver transplantation (O...
BACKGROUND: Hospital admissions are common among patients with cirrhosis, but patient factors associ...
The worldwide increase in obesity and diabetes has led to predictions that nonalcoholic steatohepati...
Purpose: Nonalcoholic steatohepatitis (NASH) is an increasing cause of liver transplantation (LT) wo...
Although hepatitis B and C have been the main drivers of hepatocellular carcinoma (HCC), nonalcoholi...
Background and Objectives: Non‐alcoholic steatohepatitis (NASH) has become the leading indication fo...
Background and Aims: With the availability of direct-acting antiviral (DAA) therapy for hepatitis C ...